top of page

Cambridge, UK based Harness Therapeutics, which topped up its seed financing this week, aims to use its oligo platform to treat Huntington's by upregulating the FAN1 nuclease across the brain

  • blonca9
  • Jan 29
  • 1 min read

CEO Jan Thirkettle describes the company's approach to upregulating genes for neurodegenerative diseases and how Harness is out front in targeting FAN1 for Huntington's.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

evaluate-logo-png_seeklogo-457165-2_edited.png

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

bottom of page